Podcast

Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer

Author(s):

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Everett Vokes, MD, John E. Ultmann Professor, physician-in-chief, and chair of the Department of Medicine at the University of Chicago Medicine. Dr. Vokes is an internationally renowned expert in head and neck cancer, having pioneered combination chemotherapy and radiation as a first-line treatment for patients.

Dr. Vokes is also the recipient of the new Translational Research Professorship from the American Society of Clinical Oncology, as well as the Francis L. Lederer Foundation grant for research on the malignancies of the upper aerodigestive tract.

In 2013, Dr. Vokes was recognized as the OncLive® Giant of Cancer Care for Head and Neck Cancer for his tremendous achievements.

In our exclusive interview, Dr. Vokes discussed the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.